Patient eligibility
systemic disease, pulmonary fibrosis
SYSTEMIC DISEASE, PULMONARY FIBROSIS, CARDIOVASCULAR DISEASE, ONCOLOGY, INTERSTITIAL LUNG DISEASE
Treatment naive NSCLCm+ with stage III, older than 18 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, were enrolled in this study between July 20, 2020, and February 10, 2022. The pathological diagnosis and Pregnant or breast-feeding patients, patients with unstable systemic disease (interstitial lung disease, pulmonary fibrosis, cardiovascular disease and so on), patients with any anticancer therapy outsides of this trial (